|1.||Brem, Henry: 15 articles (12/2015 - 02/2002)|
|2.||Olivi, Alessandro: 10 articles (12/2015 - 01/2004)|
|3.||Tyler, Betty M: 5 articles (02/2013 - 09/2003)|
|4.||McGirt, Matthew J: 5 articles (07/2010 - 09/2008)|
|5.||Weingart, Jon D: 5 articles (03/2009 - 09/2003)|
|6.||Weingart, Jon: 4 articles (12/2015 - 02/2002)|
|7.||Chaichana, Kaisorn L: 4 articles (12/2015 - 09/2008)|
|8.||Westphal, Manfred: 4 articles (01/2011 - 04/2003)|
|9.||Tyler, Betty: 3 articles (12/2015 - 02/2002)|
|10.||Menei, Philippe: 3 articles (06/2013 - 07/2010)|
|1.||Glioblastoma (Glioblastoma Multiforme)
03/01/2008 - "Preclinical and clinical studies have proven the safety and efficacy of Gliadel in the management of glioblastoma. "
08/01/2012 - "Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma."
08/01/2012 - "Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas."
01/01/2006 - "Based on Phase I/II clinical trials, the Phase III Randomized Evaluation of CED of IL13-PE Compared to Gliadel Wafer with Survival Endpoint Trial (also known as the PRECISE Trial) in patients with initial recurrence of glioblastoma multiforme has recently been completed. "
02/01/2004 - "We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL Wafers or placebo wafers following resection of glioblastomas. "
02/01/2009 - "Future trials are required to verify that inhibition of tumor AGT levels by O6-BG results in increased efficacy of Gliadel wafers without added toxicity."
10/01/2007 - "Because several randomized controlled trials (RCTS) investigating the safety and efficacy of Gliadel are available, the Neuro-oncology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care decided that a systematic review of the evidence was necessary. "
08/01/2012 - "Patients with eight Gliadel wafers implanted had a 3-fold increased risk of AE and a 5.6-fold increased risk of ISAE, and patients with recurrent tumor had a 2.8-fold increased risk of AE and a 9.3-fold increased risk of ISAE. "
11/28/2011 - "Pseudoprogression is common after intracavitary Gliadel wafer placement and thus care should be taken before diagnosing tumor progression or recurrence within the first 2 mo."
11/28/2011 - "T2-weighted/FLAIR images and post-contrast T1-weighted images both before and after wafer placement were retrospectively reviewed in consensus to determine changes in the following parameters: appearance of the pericavitary tissue, pattern of tumor recurrence or progression and appearance of the Gliadel wafer itself. "
03/01/2007 - "This study explores (1)H MRSI as a means to assess peri-tumoral tissue response post-resection and Gliadel((R)) implantation in patients with high-grade gliomas. "
03/01/2006 - "Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial."
01/01/2004 - "Randomized trials have demonstrated Gliadel improves survival for appropriately selected patients with newly diagnosed malignant glioma. "
08/01/2003 - "If the future use of Gliadel is limited to the eligibility criteria used in the phase III trial about 20% (95% confidence intervals 13-34%) of patients with newly diagnosed malignant glioma will receive this therapy."
08/01/2003 - "Only 25% of patients (14/56) with malignant glioma managed over this period were eligible for the Gliadel study and all were recruited. "
|4.||Brain Neoplasms (Brain Tumor)
08/27/1999 - "The present study provides a quantitative examination on the working principle of Gliadel wafer for the treatment of brain tumors."
01/01/2011 - "Brain tumor and Gliadel wafer treatment."
08/01/1999 - "[Gliadel--a preparation for the supplementary treatment of brain cancer]."
09/11/1998 - "Gliadel wafers for treatment of brain tumors."
01/01/2010 - "Secondary bacterial and fungal infections have been reported following Gliadel wafer placement in patients with brain tumor resection. "
|5.||Astrocytoma (Pilocytic Astrocytoma)
10/01/2008 - "In our experience, use of Gliadel wafer was not associated with an increase in perioperative morbidity after surgical treatment of malignant astrocytoma."
08/01/2013 - "Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent grade III astrocytoma."
10/01/2008 - "A total of 288 (28%) received Gliadel wafer (250 glioblastoma multiforme (GBM), 38 anaplastic astrocytoma/anaplastic oligodendroglioma (AA/AO), 166 primary resection, 122 revision resection). "
05/01/2005 - "A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme."
07/01/2010 - "Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy."
|7.||decanedioic acid- 4,4'- (1,3- propanediylbis(oxy))bis(benzoic acid) copolymer (Gliadel)
|9.||carmustine with prolifeprosan 20
|10.||Fibrin Tissue Adhesive (Fibrin Sealant)
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)